317 related articles for article (PubMed ID: 13680191)
1. Mutations and regulatory anomalies effecting tumor cell immune functions.
Blanck G
Cancer Immunol Immunother; 2004 Jan; 53(1):1-16. PubMed ID: 13680191
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunology: highlights of the NCI Extramural Immunology Program.
Austin FC; Finerty JF; Sogn JA
Cancer Invest; 1990; 8(2):207-28. PubMed ID: 2205337
[TBL] [Abstract][Full Text] [Related]
3. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.
Jardim DL; Goodman A; de Melo Gagliato D; Kurzrock R
Cancer Cell; 2021 Feb; 39(2):154-173. PubMed ID: 33125859
[TBL] [Abstract][Full Text] [Related]
4. T cell tolerance to tumors and cancer immunotherapy.
Shafer-Weaver K; Anderson M; Malyguine A; Hurwitz AA
Adv Exp Med Biol; 2007; 601():357-68. PubMed ID: 17713024
[TBL] [Abstract][Full Text] [Related]
5.
Li M; Ma Y; Zhong Y; Liu Q; Chen C; Qiang L; Wang X
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037113
[TBL] [Abstract][Full Text] [Related]
6. [Molecular bases of cancer immunology].
Barrera-Rodríguez R; Peralta-Zaragoza O; Madrid-Marina V
Salud Publica Mex; 1995; 37(4):344-53. PubMed ID: 7502157
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.
Seliger B
HLA; 2016 Nov; 88(5):213-220. PubMed ID: 27659281
[TBL] [Abstract][Full Text] [Related]
8. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.
Dhatchinamoorthy K; Colbert JD; Rock KL
Front Immunol; 2021; 12():636568. PubMed ID: 33767702
[TBL] [Abstract][Full Text] [Related]
9. Cancer Immunotherapy: Whence and Whither.
Stambrook PJ; Maher J; Farzaneh F
Mol Cancer Res; 2017 Jun; 15(6):635-650. PubMed ID: 28356330
[TBL] [Abstract][Full Text] [Related]
10. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
Li L; Li M; Wang X
DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
[TBL] [Abstract][Full Text] [Related]
11. Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor.
Srivastava N; Srivastava PK
PLoS One; 2009 Jul; 4(7):e6094. PubMed ID: 19593447
[TBL] [Abstract][Full Text] [Related]
12. Temperature matters! And why it should matter to tumor immunologists.
Repasky EA; Evans SS; Dewhirst MW
Cancer Immunol Res; 2013 Oct; 1(4):210-6. PubMed ID: 24490177
[TBL] [Abstract][Full Text] [Related]
13. The role of surface HLA-A,B,C molecules in tumour immunity.
Möller P; Hämmerling GJ
Cancer Surv; 1992; 13():101-27. PubMed ID: 1423320
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells.
Poggi A; Musso A; Dapino I; Zocchi MR
Immunol Lett; 2014; 159(1-2):55-72. PubMed ID: 24657523
[TBL] [Abstract][Full Text] [Related]
15. An acidic microenvironment inhibits antitumoral non-major histocompatibility complex-restricted cytotoxicity: implications for cancer immunotherapy.
Fischer B; Müller B; Fisch P; Kreutz W
J Immunother; 2000; 23(2):196-207. PubMed ID: 10746546
[TBL] [Abstract][Full Text] [Related]
16. The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes, and transcription factors.
Seliger B
J Immunotoxicol; 2014 Oct; 11(4):308-10. PubMed ID: 24479372
[TBL] [Abstract][Full Text] [Related]
17. Immunologic mechanisms of antitumor activity.
Foss FM
Semin Oncol; 2002 Jun; 29(3 Suppl 7):5-11. PubMed ID: 12068382
[TBL] [Abstract][Full Text] [Related]
18. HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease.
Seliger B; Ferrone S
Methods Mol Biol; 2020; 2055():325-350. PubMed ID: 31502159
[TBL] [Abstract][Full Text] [Related]
19. Major Histocompatibility Complex Genes as Therapeutic Opportunity for Immune Cold Molecular Cancer Subtypes.
Karpiński P; Łaczmański Ł; Sąsiadek MM
J Immunol Res; 2020; 2020():8758090. PubMed ID: 33282963
[TBL] [Abstract][Full Text] [Related]
20. Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy.
Wang H; Zhang X; Zhang Y; Shi T; Zhang Y; Song X; Liu B; Wang Y; Wei J
BMC Cancer; 2024 Apr; 24(1):445. PubMed ID: 38600469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
